ePrints

Toxic epidermal necrolysis occurring with immune checkpoint inhibitors

Lookup NU author(s): Dr Hudaa Gopee, Dr Thomas Oliphant, Dr Philip Hampton

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).

Abstract

Nivolumab and ipilimumab are immune checkpoint inhibitors (ICIs) used in the management of advanced malignancies including malignant melanoma. Although several cutaneous adverse events have been reported with these immunotherapy agents, toxic epidermal necrolysis (TEN) secondary to ICIs is rare. We report a 67-year-old man with TEN occurring during nivolumab and ipilimumab co-therapy and review published cases to highlight the challenges in recognizing and managing these patients. ICI-induced TEN can present atypically with delayed onset in comorbid, immunosuppressed patients with an associated high mortality rate. Prompt recognition and drug withdrawal are essential to improve outcomes. High dose systemic corticosteroid has also been recommended for the management of ICI-induced TEN, unlike other drug-induced TEN for which optimal immunomodulatory treatment is still debated.

Publication metadata

Author(s): Gopee NH, Gourley AM, Oliphant TJ, Hampton PJ

Publication type: Article

Publication status: Published

Journal: Dermatology Online Journal

Year: 2020

Volume: 26

Issue: 8

Online publication date: 01/08/2020

Acceptance date: 01/04/2018

Date deposited: 25/03/2022

ISSN (electronic): 1087-2108

Publisher: eScholarship, University of California

URL: https://doi.org/10.5070/D3268049884

DOI: 10.5070/D3268049884

PubMed id: 32941713

Altmetrics

Share